Simcere Zaiming’s Polθ Inhibitor SIM0508 Obtains New IND Approval for Combination Use with Olaparib

Novel FGFR2b-targeting ADC is approved by the U.S. FDA to enter clinical trials

NDA of Rademikibart, Jointly Developed by Simcere and Connect Biopharma for the Treatment of Atopic Dermatitis Accepted by NMPA

QUVIVIQ^® - The World’s New Generation Anti-Insomnia Drug – Approved for Launch，Significantly Improves Sleep and Daytime Functioning

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

Simcere Zaiming and NextCure Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

2025 ASCO | Simcere Zaiming Showcases the Latest Clinical Data in 18 Studies for 5 Innovative Products

Simcere Zaiming Announces Phase 3 Clinical Trial Results for Cetuximab β Injection (Enlituo)

Simcere Zaiming will present 7 innovative researches at the 2025 AACR

Simcere Zaiming’s FGFR2b targeting ADC SIM0686 obtained IND approval from China NMPA